GlassScriptPhysician profile
Shawn S Becker
NPI 1093129389
$4,425.85
in general payments reported to CMS, 2019-2025
25 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $636 · 2023: $1,127 · 2024: $1,312 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,059.46 |
| Education | $383.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $783.22 | 2021-2025 | Tremfya |
| Abbvie INC. | $751.32 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $451.11 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $406.08 | 2021-2024 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $396.97 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $228.42 | 2022-2024 | Sotyktu |
| Ucb, INC. | $203.25 | 2023-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $196.95 | 2022-2025 | Adbry |
| Amgen INC. | $162.36 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $121.95 | 2024-2025 | Opzelura |
| Pfizer INC. | $104.01 | 2021-2023 | |
| Genzyme Corporation | $90.95 | 2022-2025 | |
| Lilly USA, LLC | $79.20 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Ani Pharmaceuticals, INC. | $73.52 | 2024-2025 | Purified Cortrophin Gel |
| Dermavant Sciences, INC. | $65.88 | 2023-2024 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.58 | 2024-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $52.11 | 2023-2025 | |
| Genentech USA, INC. | $35.93 | 2023-2024 | Erivedge |
| Galderma Laboratories, L.P. | $28.92 | 2025 | Aklief, Nemluvio |
| Helsinn Therapeutics (U.S.), INC. | $27.31 | 2021-2022 | |
| Botanix Sb INC | $26.61 | 2025 | Sofdra |
| Journey Medical Corporation | $26.53 | 2022 | |
| Verrica Pharmaceuticals INC. | $23.90 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.01 | 2024 | Cabtreo |
| Organogenesis INC. | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.